Lung cancer is one of the most dangerous forms of cancer. Treatments are available, but they are demanding on patients and less than 30 percent survive. But mRNA technology is offering new hope for higher survival rates because treatments target the malignant cells in an entirely new way. In Norway, more than 3,300 people contract lung...
Tag: <span>Lung cancer</span>
Post
Getting tough on tuft cell lung cancer
Cold Spring Harbor Laboratory (CSHL) Professor Christopher Vakoc’s team discovered 2018 a new type of small-cell lung cancer. Cancer originates from cells known as tuft cells. The prognosis for tuft cell lung cancer is extremely poor. Now, the Vakoc team has discovered how tuft cells are generated in the body. Disrupting tuft cell development may...
Post
Mapping the ‘energy fingerprints’ of lung cancer leads to fundamental treatment rethink
WALTER AND ELIZA HALL INSTITUTE IMAGE: ASSOCIATE PROFESSOR KATE SUTHERLAND (L) AND DR SARAH BEST (R) CREDIT: WEHI Mapping the ‘energy fingerprints’ of lung cancer leads to fundamental treatment rethink Melbourne researchers have discovered cancer and immune cells rely on the same energy sources from our body to thrive, which could trigger a fundamental rethink...
Post
COVID-19 vaccines safe for patients treated for lung cancer with immune checkpoint inhibitors
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER (Denver—9 a.m. EDT–June 22, 2022)—Cancer patients have received priority status to receive COVID-19 vaccinations but there is limited data regarding the safety and efficacy of the vaccines for patients treated for lung cancer with immune checkpoint inhibitors. Now, a new study published in the Journal of Thoracic Oncology found...
Post
Prolonged, low-level radon exposure is still a leading cause of lung cancer
A study by the University of California, Irvine, shows a strong relationship between prolonged exposure to low radon levels and lung cancer, indicating a need for enhanced protection measures. Radon gas in the air decays into tiny radioactive particles, which can damage lung cells and lead to cancer. Findings were recently published in the online journal Environmental...
Post
Identifying new minimally invasive biomarkers for non-small cell lung cancer
by University of Missouri Credit: CC0 Public Domain In a recent study, researchers at the University of Missouri are identifying new minimally invasive biomarkers to develop a blood test for early detection of non-small cell lung cancer (NSCLC), one of two main types of lung cancer. This blood test also could help identify potential drug...
Post
Biomarker in liquid biopsy for lung cancer appears more accurate in predicting immunotherapy response than tumor biopsy
THE MOUNT SINAI HOSPITAL / MOUNT SINAI SCHOOL OF MEDICINE New York, NY (June 2, 2022) — Mount Sinai researchers have validated for the first time that a simple blood test called a liquid biopsy could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than an invasive...
Post
Nearly half of patients at high risk for lung cancer delayed screening follow-up
by American Thoracic Society Most patients at high risk failed to do lung cancer screening follow-up. Credit: ATS The first study to look at follow-up for patients deemed at high risk for lung cancer after CT screening found that 47 percent delayed follow-up care, according to research published at the ATS 2022 international conference. “The...
Post
Scientists find potential diagnostic and therapeutic target for lung cancer
JANUARY 17, 2022 by Chinese Academy of Sciences Proposed model for the LCDR/hnRNP K/LAPTM5 axis promoting the pathogenesis of lung cancer. Credit: Gao Shan Chinese scientists recently reported the key role in tumor survival played by a histone-acetylation-regulated long noncoding RNA called lysosome cell death regulator (LCDR), providing a potential diagnostic and therapeutic target for lung...
Post
Blood test helps predict who may benefit from lung cancer screening
UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER HOUSTON ― A blood test, combined with a risk model based on an individual’s history, more accurately determines who is likely to benefit from lung cancer screening than the current U.S. recommendation, according to a study published today in the Journal of Clinical Oncology led by researchers...